WO2006003526A2 - Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci - Google Patents

Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci Download PDF

Info

Publication number
WO2006003526A2
WO2006003526A2 PCT/IB2005/002630 IB2005002630W WO2006003526A2 WO 2006003526 A2 WO2006003526 A2 WO 2006003526A2 IB 2005002630 W IB2005002630 W IB 2005002630W WO 2006003526 A2 WO2006003526 A2 WO 2006003526A2
Authority
WO
WIPO (PCT)
Prior art keywords
autism
otoa
gene
disorder
alteration
Prior art date
Application number
PCT/IB2005/002630
Other languages
English (en)
Other versions
WO2006003526A3 (fr
WO2006003526A8 (fr
Inventor
Anne Phillipi
Francis Rousseau
Peter Brooks
Jörg Hager
Original Assignee
Integragen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integragen filed Critical Integragen
Publication of WO2006003526A2 publication Critical patent/WO2006003526A2/fr
Publication of WO2006003526A8 publication Critical patent/WO2006003526A8/fr
Publication of WO2006003526A3 publication Critical patent/WO2006003526A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Definitions

  • the present invention relates generally to the fields of genetics and medicine.
  • Autism is a neuropsychiatric developmental disorder characterized by impairments in reciprocal social interaction and verbal and non-verbal communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age (Bailey et al., 1996).
  • Kanner (1943) included the following symptoms: impaired language, lack of eye contact, lack of social interaction, repetitive behavior, and a rigid need for routine. He noted that in most cases the child's behavior was abnormal from early infancy. On this basis, he suggested the presence of an inborn, presumably genetic, defect.
  • Hans Asperger in Germany described similar patients and termed the condition "autistic psychopathy".
  • Autism is defined using behavioral criteria because, so far, no specific biological markers are known for diagnosing the disease.
  • the clinical picture of autism varies in severity and is modified by many factors, including education, ability and temperament. Furthermore, the clinical picture changes over the course of the development within an individual.
  • autism is frequently associated with other disorders such as attention deficit disorder, motor incoordination and psychiatric symptoms such as anxiety and depression.
  • autism may also encompass epileptic, metabolic and immune disorder.
  • autistic disorders which includes individuals at all levels of intelligence and language ability and spanning all degrees of severity.
  • AS Asperger syndrome
  • PPD pervasive developmental disorders
  • PPD-NOS pervasive developmental disorders
  • autism is no longer considered a rare disorder.
  • Higher rates of 10-12 cases per 10,000 individuals have been reported in more recent studies (Gillberg and Wing, 1999) compared to the previously reported prevalence rate of 4-5 patients per 10,000 individuals based on Kanner's criteria (Folstein and Rosen-Sheidley, 2001).
  • Estimates for the prevalence rate of the full spectrum of autistic disorders are 1.5 to 2.5 times higher. Reports of a four times higher occurrence in males compared to females are consistent.
  • Mental retardation is present in between 25% and 40% of cases with ASD (Baird et al. 2000; Chakrabarti and Fombonne, 2001). Additional medical conditions involving the brain are seen in ca. 10% of the population (Gillberg and Coleman, 2000).
  • the present invention now discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism, autism spectrum disorders, and autism-associated disorders, as well as for the screening of therapeutically active drugs.
  • the present invention more particularly discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs.
  • the invention more specifically discloses certain alleles of the otoancorin (OTOA) gene related to susceptibility to autism and representing novel targets for therapeutic intervention.
  • OTOA otoancorin
  • the present invention relates to particular mutations in the OTOA gene and expression products, as well as to diagnostic tools and kits based on these mutations.
  • the invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, childhood disintegrative disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay or language impairment, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia.
  • the invention can be used in the diagnosis of predisposition to or protection from, detection, prevention and/or treatment of autism, an autism spectrum disorder, or an autism-associated disorder, the method comprising detecting in a sample from the subject the presence of an alteration in the OTOA gene or polypeptide, the presence of said alteration being indicative of the presence or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder.
  • the presence of said alteration can also be indicative for protecting from autism.
  • a particular object of this invention resides in a method of detecting the presence of or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising detecting the presence of an alteration in the OTOA gene locus in a sample from the subject, the presence of said alteration being indicative of the presence of or the predisposition to autism, an autism spectrum disorder, or an autism- associated disorder.
  • An alteration being indicative of the presence of or the predisposition to autism, an autism spectrum disorder, or an autism-associated disorder is an alteration with a preferential transmission to autists.
  • an alteration being indicative of the presence of or the predisposition to autism, an autism spectrum disorder, or an autism- associated disorder is an alteration with a higher frequency in autists compared to non affected individuals.
  • An additional particular object of this invention resides in a method of detecting the protection from autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising detecting the presence of an alteration in the OTOA gene locus in a sample from the subject, the presence of said alteration being indicative of the protection from autism, an autism spectrum disorder, or an autism-associated disorder.
  • An alteration being indicative of the protection from autism, an autism spectrum disorder, or an autism-associated disorder is an alteration with a preferential non-transmission to autists.
  • an alteration being indicative of the protection from autism, an autism spectrum disorder, or an autism-associated disorder is an alteration with a lower frequency in autists compared to non affected individuals.
  • Another particular object of this invention resides in a method of assessing the response of a subject to a treatment of autism, an autism spectrum disorder, or an autism-associated disorder, the method comprising detecting the presence of an alteration in the OTOA gene locus in a sample from the subject, the presence of said alteration being indicative of a particular response to said treatment.
  • a further particular object of this invention resides in a method of assessing the adverse effect in a subject to a treatment of autism, an autism spectrum disorder, or an autism- associated disorder, the method comprising detecting the presence of an alteration in the OTOA gene locus in a sample from the subject, the presence of said alteration being indicative of an adverse effect to said treatment.
  • This invention also relates to a method for preventing autism, an autism spectrum disorder, or an autism-associated disorder in a subject, comprising detecting the presence of an alteration in the OTOA gene locus in a sample from the subject, the presence of said alteration being indicative of the predisposition to autism, an autism spectrum disorder, or an autism-associated disorder; and, administering a prophylactic treatment against autism, an autism spectrum disorder, or an autism-associated disorder.
  • said alteration is one or several SNP(s) or a haplotype of SNPs associated with autism.
  • said haplotype associated with autism comprises or consists of several SNPs selected from the group consisting of SNP62, SNP67, SNP71, SNP72 and SNP75.
  • said haplotype is selected from the haplotypes disclosed in Table 4. More preferably, said SNP associated with autism can be SNP67.
  • the alteration in the OTOA gene locus is determined by performing a hydridization assay, a sequencing assay, a microsequencing assay, an oligonucleotide ligation assay, a confirmation based assay, a melting curve analysis, a denaturing high performance liquid chromatography (DHPLC) assay or an allele-specific amplification assay.
  • a hydridization assay e.g., a sequencing assay, a microsequencing assay, an oligonucleotide ligation assay, a confirmation based assay, a melting curve analysis, a denaturing high performance liquid chromatography (DHPLC) assay or an allele-specific amplification assay.
  • a hydridization assay e.g., a sequencing assay, a microsequencing assay, an oligonucleotide ligation assay, a confirmation based assay, a melting curve analysis,
  • a particular aspect of this invention resides in compositions of matter comprising primers, probes, and/or oligonucleotides, which are designed to specifically detect at least one SNP or haplotype associated with autism in the genomic region including the OTOA gene, or a combination thereof.
  • said haplotype associated with autism comprises or consists of several SNPs selected from the group consisting of SNP62, SNP67, SNP71 , SNP72 and SNP75.
  • said haplotype is selected from the haplotypes disclosed in Table 4. More preferably, said SNP associated with autism can be SNP67.
  • the invention also resides in methods of treating autism and/or associated disorders in a subject through a modulation of OTOA expression or activity.
  • Such treatments use, for instance, OTOA polypeptides, OTOA DNA sequences (including antisense sequences and RNAi directed at the OTOA gene locus), anti- OTOA antibodies or drugs that modulate OTOA expression or activity.
  • the invention also relates to methods of treating individuals who carry deleterious alleles of the OTOA gene, including pre-symptomatic treatment or combined therapy, such as through gene therapy, protein replacement therapy or through the administration of OTOA protein mimetics and/or inhibitors.
  • a further aspect of this invention resides in the screening of drugs for therapy of autism or associated disorder, based on the modulation of or binding to an allele of OTOA gene associated with autism or associated disorder or gene product thereof.
  • a further aspect of this invention includes antibodies specific of OTOA polypeptide fragments and derivatives of such antibodies, hybridomas secreting such antibodies, and diagnostic kits comprising those antibodies. More preferably, said antibodies are specific to an OTOA polypeptide or a fragment thereof comprising an alteration, said alteration modifying the activity of OTOA.
  • the invention also concerns an OTOA gene or a fragment thereof comprising an alteration, said alteration modifying the activity of OTOA.
  • the invention further concerns an OTOA polypeptide or a fragment thereof comprising an alteration, said alteration modifying the activity of OTO A.
  • FIG 1 High density mapping using Genomic Hybrid Identity Profiling (GenomeHIP) A total of 2263 BAC clones with an average spacing of 1.2 Mega base pairs between clones representing the whole human genome were tested for linkage using GenomeHIP. Each point corresponds to a clone. Significant evidence for linkage was calculated for clone BACA4ZA08 (p-value 6.4x10 "7 ). The whole linkage region encompasses a region from 134095595 base pairs to 135593528 base pairs on human chromosome 16. The p- value 2x10 "5 corresponding to the significance level for significant linkage was used as a significance level for whole genome screens as proposed by Lander and Kruglyak ( 1995).
  • GeneHIP Genomic Hybrid Identity Profiling
  • the present invention discloses the identification of OTOA as a human autism susceptibility gene.
  • Various nucleic acid samples from 1 14 families with autism were submitted to a particular GenomeHIP process. This process led to the identification of particular identical-by-descent fragments in said populations that are altered in autistic subjects.
  • OTOA otoancorin gene on chromosome 16pl2.2
  • This gene is indeed present in the critical interval and expresses a functional phenotype consistent with a genetic regulation of autism.
  • SNPs of the OTOA gene were also identified, as being correlated to autism in human subjects.
  • SNP67 located in the OTOA gene locus was found to be associated with autism.
  • Haplotypes disclosed in Table 4 comprising several SNPs selected from the group consisting of SNP62, SNP67, SNP71 , SNP72 and SNP75 have also been identified as associated with autism.
  • the present invention thus proposes to use OTOA gene and corresponding expression products for the diagnosis, prevention and treatment of autism, autism spectrum disorders, and autism-associated disorders, as well as for the screening of therapeutically active drugs.
  • Autism and autism spectrum disorders Autism is typically characterized as part of a spectrum of disorders (ASDs) including Asperger syndrome (AS) and other pervasive developmental disorders (PPD). Autism shall be construed as any condition of impaired social interaction and communication with restricted repetitive and stereotyped patterns of behavior, interests and activities present before the age of 3, to the extent that health may be impaired. AS is distinguished from autistic disorder by the lack of a clinically significant delay in language development in the presence of the impaired social interaction and restricted repetitive behaviors, interests, and activities that characterize the autism- spectrum disorders (ASDs). PPD-NOS (PPD, not otherwise specified) is used to categorize children who do not meet the strict criteria for autism but who come close, either by manifesting atypical autism or by nearly meeting the diagnostic criteria in two or three of the key areas.
  • PPD-NOS PPD, not otherwise specified
  • Autism-associated disorders, diseases or pathologies include, more specifically, any metabolic and immune disorders, epilepsy, anxiety, depression, attention deficit hyperactivity disorder, speech delay or language impairment, motor incoordination, mental retardation, schizophrenia and bipolar disorder.
  • the invention may be used in various subjects, particularly human, including adults, children and at the prenatal stage.
  • the OTOA gene locus designates all OTOA sequences or products in a cell or organism, including OTOA coding sequences, OTOA non-coding sequences (e.g., introns), OTOA regulatory sequences controlling transcription and/or translation (e.g., promoter, enhancer, terminator, etc.), as well as all corresponding expression products, such as OTOA RNAs (e.g., mRNAs) and OTOA polypeptides (e.g., a pre-protein and a mature protein).
  • the OTOA gene locus also comprise surrounding sequences of the OTOA gene which include SNPs that are in linkage disequilibrium with SNPs located in the OTOA gene.
  • the OTOA locus comprises surrounding sequences comprising SNP62, SNP67, SNP71, SNP72, and SNP75.
  • OTOA gene designates the otoancorin gene on human chromosome 16pl2.2, as well as variants, analogs and fragments thereof, including alleles thereof (e.g., germline mutations) which are related to susceptibility to autism and autism-associated disorders.
  • gene shall be construed to include any type of coding nucleic acid, including genomic DNA (gDNA), complementary DNA (cDNA), synthetic or semi-synthetic DNA, as well as any form of corresponding RNA.
  • the term gene particularly includes recombinant nucleic acids encoding OTOA, i.e., any non naturally occurring nucleic acid molecule created artificially, e.g., by assembling, cutting, ligating or amplifying sequences.
  • An OTOA gene is typically double-stranded, although other forms may be contemplated, such as single-stranded.
  • OTOA genes may be obtained from various sources and according to various techniques known in the art, such as by screening DNA libraries or by amplification from various natural sources.
  • Recombinant nucleic acids may be prepared by conventional techniques, including chemical synthesis, genetic engineering, enzymatic techniques, or a combination thereof.
  • Suitable OTOA gene sequences may be found on gene banks, such as Unigene Cluster for OTOA (Hs.408336) and Unigene Representative
  • a particular example of an OTOA gene comprises SEQ ID No: 1.
  • OTOA gene includes any variant, fragment or analog of SEQ ID No 1 or of any coding sequence as identified above. Such variants include, for instance, natural Iy- occurring variants due to allelic variations between individuals (e.g., polymorphisms), mutated alleles related to autism, alternative splicing forms, etc.
  • the term variant also includes OTOA gene sequences from other sources or organisms. Variants are preferably substantially homologous to SEQ ID No 1 , i.e., exhibit a nucleotide sequence identity of at least about 65%, typically at least about 75%, preferably at least about 85%, more preferably at least about 95% with SEQ ID No 1. Variants and analogs of an OTOA gene also include nucleic acid sequences, which hybridize to a sequence as defined above (or a complementary strand thereof) under stringent hybridization conditions.
  • Typical stringent hybridisation conditions include temperatures above 30° C, preferably above 35°C, more preferably in excess of 42°C, and/or salinity of less than about 500 mM, preferably less than 200 mM.
  • Hybridization conditions may be adjusted by the skilled person by modifying the temperature, salinity and/or the concentration of other reagents such as SDS, SSC, etc.
  • a fragment of an OTOA gene designates any portion of at least about 8 consecutive nucleotides of a sequence as disclosed above, preferably at least about 15, more preferably at least about 20 nucleotides, further preferably of at least 30 nucleotides. Fragments include all possible nucleotide lengths between 8 and 100 nucleotides, preferably between 15 and 100, more preferably between 20 and 100.
  • An OTOA polypeptide designates any protein or polypeptide encoded by an OTOA gene as disclosed above.
  • polypeptide refers to any molecule comprising a stretch of amino acids. This term includes molecules of various lengths, such as peptides and proteins.
  • the polypeptide may be modified, such as by glycosylations and/or acetylations and/or chemical reaction or coupling, and may contain one or several non-natural or synthetic amino acids.
  • a specific example of an OTOA polypeptide comprises all or part of SEQ ID No: 2 (NP_653173).
  • response to a treatment refers to treatment efficacy, including but not limited to ability to metabolise a therapeutic compound, to the ability to convert a pro-drug to an active drug, and to the pharmacokinetics (absorption, distribution, elimination) and the pharmacodynamics (receptor-related) of a drug in an individual.
  • adverse effects to a treatment refer to adverse effects of therapy resulting from extensions of the principal pharmacological action of the drug or to idiosyncratic adverse reactions resulting from an interaction of the drug with unique host factors.
  • “Side effects to a treatment” include, but are not limited to, adverse reactions such as dermatologic, hematologic or- hepatologic toxicities and further includes gastric and intestinal ulceration, disturbance in platelet function, renal injury, generalized urticaria, bronchoconstriction, hypotension, and shock.
  • the invention now provides diagnosis methods based on a monitoring of the OTOA gene locus in a subject.
  • diagnosis includes the detection, monitoring, dosing, comparison, etc., at various stages, including early, pre-symptomatic stages, and late stages, in adults, children and pre-birth.
  • Diagnosis typically includes the prognosis, the assessment of a predisposition or risk of development, the characterization of a subject to define most appropriate treatment (pharmacogenetics), etc.
  • the present invention provides diagnostic methods to determine whether an individual is at risk of developing autism, an autism spectrum disorder, or an autism-associated disorder or suffers from autism, an autism spectrum disorder, or an autism-associated disorder resulting from a mutation or a polymorphism in the OTOA gene locus.
  • the present invention also provides methods to determine whether an individual is likely to respond positively to a therapeutic agent or whether an individual is at risk of developing an adverse side effect to a therapeutic agent.
  • a particular object of this invention resides in a method of detecting the presence of or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising detecting in a sample from the subject the presence of an alteration in the OTOA gene locus in said sample. The presence of said alteration is indicative of the presence or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder.
  • said method comprises a previous step of providing a sample from a subject.
  • the presence of an alteration in the OTOA gene locus in said sample is detected through the genotyping of a sample.
  • Another particular object of this invention resides in a method of detecting the protection from autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising detecting the presence of an alteration in the OTOA gene locus in a sample from the subject, the presence of said alteration being indicative of the protection from autism, an autism spectrum disorder, or an autism-associated disorder.
  • said alteration is one or several SNP(s) or a haplotype of SNPs associated with autism.
  • said haplotype associated with autism comprises or consists of several SNPs selected from the group consisting of SNP62, SNP67, SNP71, SNP72 and SNP75.
  • said haplotype is selected from the haplotypes disclosed in Table 4. More preferably, said SNP associated with autism is SNP67.
  • Another particular object of this invention resides in a method of assessing the response of a subject to a treatment of autism, an autism spectrum disorder, or an autism-associated disorder, the method comprising (i) providing a sample from the subject and (ii) detecting the presence of an alteration in the OTOA gene locus in said sample.
  • Another particular object of this invention resides in a method of assessing the response of a subject to a treatment of autism, an autism spectrum disorder, or an autism-associated disorder, the method comprising detecting in a sample from the subject the presence of an alteration in the OTOA gene locus in said sample.
  • the presence of said alteration is indicative of a particular response to said treatment.
  • the presence of an alteration in the OTOA gene locus in said sample is detected through the genotyping of a sample.
  • a further particular object of this invention resides in a method of assessing the adverse effects of a subject to a treatment of autism, an autism spectrum disorder, or an autism- associated disorder, the method comprising detecting in a sample from the subject the presence of an alteration in the OTOA gene locus in said sample.
  • the presence of said alteration is indicative of adverse effects to said treatment.
  • the presence of an alteration in the OTOA gene locus in said sample is detected through the genotyping of a sample.
  • said alteration is one or several SNP(s) or a haplotype of SNPs associated with autism.
  • said haplotype associated with autism comprises or consists of several SNPs selected from the group consisting of SNP62, SNP67, SNP71, SNP72 and SNP75.
  • said haplotype is selected from the haplotypes disclosed in Table 4. More preferably, said SNP associated with autism is SNP67.
  • the invention concerns a method for preventing autism, an autism spectrum disorder, or an autism-associated disorder in a subject, comprising detecting the presence of an alteration in the OTOA gene locus in a sample from the subject, the presence of said alteration being indicative of the predisposition to autism, an autism spectrum disorder, or an autism-associated disorder; and, administering a prophylactic treatment against autism, an autism spectrum disorder, or an autism-associated disorder.
  • Said prophylactic treatment can be a drug administration.
  • Said prophylactic treatment can also be a behavioral therapy.
  • Diagnostics which analyse and predict response to a treatment or drug, or side effects to a treatment or drug, may be used to determine whether an individual should be treated with a particular treatment drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects. Clinical drug trials represent another application for the OTOA SNPs. One or more OTOA
  • SNPs indicative of response to a drug or to side effects to a drug may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.
  • Clinical trials to assess the utility of a behavioural therapy are also an application for the OTOA SNPs.
  • One or more OTOA SNPs indicative of response to a behavioural therapy or to side effects to a behavioral therapy may be identified using the methods described above. Thereafter, potential participants in clinical trials of such a therapy may be screened to identify those individuals most likely to respond favorably to the therapy and exclude those likely to experience side effects. In that way, the effectiveness of behavioral treatment may be measured in individuals who respond positively to the therapy, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.
  • the alteration may be determined at the level of the OTOA gDNA, RNA or polypeptide.
  • the detection is determined by performing a hydridization assay, a sequencing assay, a microsequencing assay, an oligonucleotide ligation assay, a confirmation based assay, a melting curve analysis, a denaturing high performance liquid chromatography (DHPLC) assay (Jones et al, 2000) or an allele-specific amplification assay.
  • the detection is performed by sequencing all or part of the OTOA gene or by selective hybridisation or amplification of all or part of the OTOA gene. More preferably an OTOA gene specific amplification is carried out before the alteration identification step.
  • An alteration in the OTOA gene locus may be any form of mutation(s), deletion(s), rearrangement(s) and/or insertions in the coding and/or non-coding region of the locus, alone or in various combination(s). Mutations more specifically include point mutations. Deletions may encompass any region of one, two or more residues in a coding or non- coding portion of the gene locus, such as from two residues up to the entire gene or locus. Typical deletions affect smaller regions, such as domains (introns) or repeated sequences or fragments of less than about 50 consecutive base pairs, although larger deletions may occur as well. Insertions may encompass the addition of one or several residues in a coding or non-coding portion of the gene locus.
  • Insertions may typically comprise an addition of between 1 and 50 base pairs in the gene locus. Rearrangement includes inversion of sequences.
  • the OTOA gene locus alteration may result in the creation of stop codons, frameshift mutations, amino acid substitutions, particular RNA splicing or processing, product instability, truncated polypeptide production, etc.
  • the alteration may result in the production of an OTOA polypeptide with altered function, stability, targeting or structure.
  • the alteration may also cause a reduction in protein expression or, alternatively, an increase in said production.
  • the alteration in the OTOA gene locus is selected from a point mutation, a deletion and an insertion in the OTOA gene or corresponding expression product, more preferably a point mutation and a deletion.
  • the alteration may be determined at the level of the OTOA gDTNA, RNA or polypeptide.
  • the present invention now discloses a SNP in the OTOA gene and certain haplotypes, which include SNPs selected from the group consisting of SNP62, SNP67, SNP71, SNP72 and SNP75, that are associated with autism.
  • SNPs are reported in the following Table 1.
  • one or several SNP in the OTOA gene and certain haplotypes comprising SNP in the OTOA gene, more particularly SNP62, SNP67, SNP71, SNP72 and SNP75, can be used in combination with other SNP or haplotype associated with autism, an autism spectrum disorder, or an autism-associated disorder and located in other gene(s).
  • the method comprises detecting the presence of an altered OTOA RNA expression.
  • Altered RNA expression includes the presence of an altered RNA sequence, the presence of an altered RNA splicing or processing, the presence of an altered quantity of RNA, etc. These may be detected by various techniques known in the art, including by sequencing all or part of the OTOA RNA or by selective hybridisation or selective amplification of all or part of said RNA, for instance.
  • the method comprises detecting the presence of an altered OTOA polypeptide expression.
  • Altered OTOA polypeptide expression includes the presence of an altered polypeptide sequence, the presence of an altered quantity of OTOA polypeptide, the presence of an altered tissue distribution, etc. These may be detected by various techniques known in the art, including by sequencing and/or binding to specific ligands (such as antibodies), for instance.
  • oligonucleotide ASO
  • oligonucleotide ligation allele-specific amplification
  • Southern blot for DNAs
  • Northern blot for RNAs
  • SSCA single- stranded conformation analysis
  • FISH fluorescent in situ hybridization
  • Some of these approaches are based on a change in electrophoretic mobility of the nucleic acids, as a result of the presence of an altered sequence. According to these techniques, the altered sequence is visualized by a shift in mobility on gels. The fragments may then be sequenced to confirm the alteration.
  • Some others are based on specific hybridisation between nucleic acids from the subject and a probe specific for wild type or altered OTOA gene or RNA.
  • the probe may be in suspension or immobilized on a substrate.
  • the probe is typically labeled to facilitate detection of hybrids.
  • Some of these approaches are particularly suited for assessing a polypeptide sequence or expression level, such as Northern blot, ELlSA and RIA. These latter require the use of a ligand specific for the polypeptide, more preferably of a specific antibody.
  • the method comprises detecting the presence of an altered OTOA gene expression profile in a sample from the subject. As indicated above, this can be accomplished more preferably by sequencing, selective hybridisation and/or selective amplification of nucleic acids present in said sample. Sequencing
  • Sequencing can be carried out using techniques well known in the art, using automatic sequencers.
  • the sequencing may be performed on the complete OTOA gene or, more preferably, on specific domains thereof, typically those known or suspected to carry deleterious mutations or other alterations.
  • Amplification is based on the formation of specific hybrids between complementary nucleic acid sequences that serve to initiate nucleic acid reproduction.
  • Amplification may be performed according to various techniques known in the art, such as by polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA) and nucleic acid sequence based amplification (NASBA). These techniques can be performed using commercially available reagents and protocols. Preferred techniques use allele-specific PCR or PCR-SSCP. Amplification usually requires the use of specific nucleic acid primers, to initiate the reaction.
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • SDA strand displacement amplification
  • NASBA nucleic acid sequence based amplification
  • Nucleic acid primers useful for amplifying sequences from the OTOA gene or locus are able to specifically hybridize with a portion of the OTOA gene locus that flank a target region of said locus, said target region being altered in certain subjects having autism, an autism spectrum disorder, or an autism-associated disorder. Examples of such target regions are provided in Table 1.
  • Primers that can be used to amplify OTOA target region comprising SNPs as identified in Table 1 may be designed based on the sequence of Seq Id No 1 or on the genomic sequence of OTOA. In a particular embodiment, primers may be designed based on the sequence of SEQ ID Nos 3-7.
  • nucleic acid primer useful for amplifying sequences from the OTOA gene or locus including surrounding regions.
  • Such primers are preferably complementary to, and hybridize specifically to nucleic acid sequences in the OTOA gene locus.
  • Particular primers are able to specifically hybridise with a portion of the OTOA gene locus that flank a target region of said locus, said target region being altered in certain subjects having autism, an autism spectrum disorder, or an autism-associated disorder.
  • the invention also relates to a nucleic acid primer, said primer being complementary to and hybridizing specifically to a portion of an OTOA coding sequence (e.g., gene or RNA) altered in certain subjects having autism, an autism spectrum disorder, or an autism- associated disorder.
  • an OTOA coding sequence e.g., gene or RNA
  • particular primers of this invention are specific for altered sequences in an OTOA gene or RNA.
  • Typical primers of this invention are single-stranded nucleic acid molecules of about 5 to 60 nucleotides in length, more preferably of about 8 to about 25 nucleotides in length.
  • the sequence can be derived directly from the sequence of the OTOA gene locus. Perfect complementarity is preferred, to ensure high specificity. However, certain mismatch may be tolerated.
  • the invention also concerns the use of a nucleic acid primer or a pair of nucleic acid primers as described above in a method of detecting the presence of or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder in a subject or in a method of assessing the response of a subject to a treatment of autism, an autism spectrum disorder, or an autism-associated disorder.
  • Hybridization detection methods are based on the formation of specific hybrids between complementary nucleic acid sequences that serve to detect nucleic acid sequence alteration(s).
  • a particular detection technique involves the use of a nucleic acid probe specific for wild type or altered OTOA gene or RNA, followed by the detection of the presence of a hybrid.
  • the probe may be in suspension or immobilized on a substrate or support (as in nucleic acid array or chips technologies).
  • the probe is typically labeled to facilitate detection of hybrids.
  • a particular embodiment of this invention comprises contacting the sample from the subject with a nucleic acid probe specific for an altered OTOA gene locus, and assessing the formation of an hybrid.
  • the method comprises contacting simultaneously the sample with a set of probes that are specific, respectively, for wild type OTOA gene locus and for various altered forms thereof.
  • it is possible to detect directly the presence of various forms of alterations in the OTOA gene locus in the sample.
  • various samples from various subjects may be treated in parallel.
  • a probe refers to a polynucleotide sequence which is complementary to and capable of specific hybridisation with a (target portion of a) OTOA gene or RNA, and which is suitable for detecting polynucleotide polymorphisms associated with OTOA alleles which predispose to or are associated with autism, an autism spectrum disorder, or an autism-associated disorder.
  • Probes are preferably perfectly complementary to the OTOA gene, RNA, or target portion thereof.
  • Probes typically comprise single- stranded nucleic acids of between 8 to 1000 nucleotides in length, for instance of between 10 and 800, more preferably of between 15 and 700, typically of between 20 and 500. It should be understood that longer probes may be used as well.
  • a preferred probe of this invention is a single stranded nucleic acid molecule of between 8 to 500 nucleotides in length, which can specifically hybridise to a region of an OTOA gene or RNA that carries an alteration.
  • a specific embodiment of this invention is a nucleic acid probe specific for an altered (e.g., a mutated) OTOA gene or RNA, i.e., a nucleic acid probe that specifically hybridises to said altered OTOA gene or RNA and essentially does not hybridise to an OTOA gene or
  • RNA lacking said alteration indicates that hybridisation to the target sequence generates a specific signal which can be distinguished from the signal generated through non-specific hybridisation. Perfectly complementary sequences are preferred to design probes according to this invention. It should be understood, however, that certain a certain degree of mismatch may be tolerated, as long as the specific signal may be distinguished from non-specific hybridisation.
  • probes are nucleic acid sequences complementary to a target portion of the genomic region including the OTOA gene or RNA carrying a point mutation as listed in Table 1 above. More particularly, the probes can comprise a sequence selected from the group consisting of SEQ ID Nos 3-7 or a fragment thereof comprising the SNP or a complementary sequence thereof.
  • the sequence of the probes can be derived from the sequences of the OTOA gene and RNA as provided in the present application. Nucleotide substitutions may be performed, as well as chemical modifications of the probe. Such chemical modifications may be accomplished to increase the stability of hybrids (e.g., intercalating groups) or to label the probe. Typical examples of labels include, without limitation, radioactivity, fluorescence, luminescence, enzymatic labeling, etc.
  • the invention also concerns the use of a nucleic acid probe as described above in a method of detecting the presence of or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder in a subject or in a method of assessing the response of a subject to a treatment of autism, an autism spectrum disorder, or an autism-associated disorder.
  • the oligonucleotide ligation assay is a method consists of designing 3 specific primers per
  • SNP SNP with two primers carrying the SNP-base specific 3' end and one common primer that starts 5' with the next base in the target sequence.
  • the two allele specific primers carry a tag of unique sequences that determine each allele.
  • Primers are annealed to the target sequence and a ligation reaction will join the allele specific primer with the common primer if the allele specific 3'-base is present.
  • a short fluorescent dye labelled probe homologous to the tag of unique sequence is then hybridised to the immobilized product enabling the detection of the corresponding allele.
  • An oligo-ligation kit is commercially available (SNPlex, Applied Biosystems, Foster City).
  • alteration in the OTOA gene locus may also be detected by screening for alteration(s) in OTOA polypeptide sequence or expression levels.
  • a specific embodiment of this invention comprises contacting the sample with a ligand specific for an OTOA polypeptide and determining the formation of a complex.
  • ligands may be used, such as specific antibodies.
  • the sample is contacted with an antibody specific for an OTOA polypeptide and the formation of an immune complex is determined.
  • Various methods for detecting an immune complex can be used, such as ELISA, radioimmunoassays (RIA) and immuno- enzymatic assays (IEMA).
  • an antibody designates a polyclonal antibody, a monoclonal antibody, as well as fragments or derivatives thereof having substantially the same antigen specificity. Fragments include Fab, Fab'2, CDR regions, etc. Derivatives include single-chain antibodies, humanized antibodies, poly-functional antibodies, etc.
  • An antibody specific for an OTOA polypeptide designates an antibody that selectively binds an OTOA polypeptide, namely, an antibody raised against an OTOA polypeptide or an epitope-containing fragment thereof. Although non-specific binding towards other antigens may occur, binding to the target OTOA polypeptide occurs with a higher affinity and can be reliably discriminated from non-specific binding.
  • the method comprises contacting a sample from the subject with (a support coated with) an antibody specific for an altered form of an OTOA polypeptide, and determining the presence of an immune complex.
  • the sample may be contacted simultaneously, or in parallel, or sequentially, with various (supports coated with) antibodies specific for different forms of an OTOA polypeptide, such as a wild type and various altered forms thereof.
  • the invention also concerns the use of a ligand, preferably an antibody, a fragment or a derivative thereof as described above, in a method of detecting the presence of or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder in a subject or in a method of assessing the response of a subject to a treatment of autism, an autism spectrum disorder, or an autism-associated disorder.
  • a ligand preferably an antibody, a fragment or a derivative thereof as described above
  • the invention also relates to a diagnostic kit comprising products and reagents for detecting in a sample from a subject the presence of an alteration in the OTOA gene or polypeptide, in the OTOA gene or polypeptide expression, and/or in OTOA activity.
  • Said diagnostic kit according to the present invention comprises any primer, any pair of primers, any nucleic acid probe and/or any ligand, preferably antibody, described in the present invention.
  • Said diagnostic kit according to the present invention can further comprise reagents and/or protocols for performing a hybridization, amplification or antigen-antibody immune reaction.
  • the diagnosis methods can be performed in vitro, ex vivo or in vivo, preferably in vitro or ex vivo. They use a sample from the subject, to assess the status of the OTOA gene locus.
  • the sample may be any biological sample derived from a subject, which contains nucleic acids or polypeptides. Examples of such samples include fluids, tissues, cell samples, organs, biopsies, etc. Most preferred samples are blood, plasma, saliva, urine, seminal fluid, etc. Pre-natal diagnosis may also be performed by testing fetal cells or placental cells, for instance.
  • the sample may be collected according to conventional techniques and used directly for diagnosis or stored. The sample may be treated prior to performing the method, in order to render or improve availability of nucleic acids or polypeptides for testing.
  • Treatments include, for instant, lysis (e.g., mechanical, physical, chemical, etc.), centrifugation, etc.
  • the nucleic acids and/or polypeptides may be pre-purified or enriched by conventional techniques, and/or reduced in complexity. " Nucleic acids and polypeptides may also be treated with enzymes or other chemical or physical treatments to produce fragments thereof. Considering the high sensitivity of the claimed methods, very few amounts of sample are sufficient to perform the assay.
  • the sample is preferably contacted with reagents such as probes, primers or ligands in order to assess the presence of an altered OTOA gene locus.
  • Contacting may be performed in any suitable device, such as a plate, tube, well, glass, etc.
  • the contacting is performed on a substrate coated with the reagent, such as a nucleic acid array or a specific ligand array.
  • the substrate may be a solid or semi-solid substrate such as any support comprising glass, plastic, nylon, paper, metal, polymers and the like.
  • the substrate may be of various forms and sizes, such as a slide, a membrane, a bead, a column, a gel, etc.
  • the contacting may be made under any condition suitable for a complex to be formed between the reagent and the nucleic acids or polypeptides of the sample.
  • the finding of an altered OTOA polypeptide, RNA or DNA in the sample is indicative of the presence of an altered OTOA gene locus in the subject, which can be correlated to the presence, predisposition or stage of progression of autism, an autism spectrum disorder, or an autism-associated disorder.
  • an individual having a germ line OTOA mutation has an increased risk of developing autism, an autism spectrum disorder, or an autism-associated disorder.
  • the determination of the presence of an altered OTOA gene locus in a subject also allows the design of appropriate therapeutic intervention, which is more effective and customized. Also, this determination at the pre-symptomatic level allows a preventive regimen to be applied.
  • OTOA gene locus the practitioner of ordinary skill in the art can easily identify additional SNPs in linkage disequilibrium with this first SNP. Indeed, any SNP in linkage disequilibrium with a first SNP associated with autism or an associated disorder will be associated with this trait. Therefore, once the association has been demonstrated between a given SNP and autism or an associated disorder, the discovery of additional SNPs associated with this trait can be of great interest in order to increase the density of SNPs in this particular region.
  • Identification of additional SNPs in linkage disequilibrium with a given SNP involves: (a) amplifying a fragment from the genomic region comprising or surrounding a first SNP from a plurality of individuals; (b) identifying of second SNPs in the genomic region harboring or surrounding said first SNP; (c) conducting a linkage disequilibrium analysis between said first SNP and second SNPs; and (d) selecting said second SNPs as being in linkage disequilibrium with said first marker. Subcombinations comprising steps (b) and (c) are also contemplated.
  • SNPs in linkage disequilibrium can also be used in the methods according to the present invention, and more particularly in the diagnosic methods according to the present invention.
  • a linkage locus of Crohn's disease has been mapped to a large region spanning 18cM on chromosome 5q31 (Rioux et al., 2000 and 2001).
  • LD linkage disequilibrium
  • the authors developed an ultra-high-density SNP map and studied a denser collection of markers selected from this map.
  • Multilocus analyses defined a single common risk haplotype characterised by multiple SNPs that were each independently associated using TDT. These SNPs were unique to the risk haplotype and essentially identical in their information content by virtue of being in nearly complete LD with one another. The equivalent properties of these SNPs make it impossible to identify the causal mutation within this region on the basis of genetic evidence alone.
  • Mutations in the OTOA gene which are responsible for autism or an associated disorder may be identified by comparing the sequences of the OTOA gene from patients presenting autism or an associated disorder and control individuals. Based on the identified association of SNPs of OTOA and autism or an associated disorder, the identified locus can be scanned for mutations. In a preferred embodiment, functional regions such as exons and splice sites, promoters and other regulatory regions of the OTOA gene are scanned for mutations.
  • patients presenting autism or an associated disorder carry the mutation shown to be associated with autism or an associated disorder and controls individuals do not carry the mutation or allele associated with autism or an associated disorder. It might also be possible that patients presenting autism or an associated disorder carry the mutation shown to be associated with autism or an associated disorder with a higher frequency than controls individuals.
  • the method used to detect such mutations generally comprises the following steps: amplification of a region of the OTOA gene comprising a SNP or a group of SNPs associated with autism or an associated disorder from DNA samples of the OTOA gene from patients presenting autism or an associated disorder and control individuals; sequencing of the amplified region; comparison of DNA sequences of the OTOA gene from patients presenting autism or an associated disorder and control individuals; determination of mutations specific to patients presenting autism or an associated disorder.
  • identification of a causal mutation in the OTOA gene can be carried out by the skilled person without undue experimentation by using well-known methods.
  • causal mutations have been identified in the following examples by using routine methods.
  • Hugot et al. (2001) applied a positional cloning strategy to identify gene variants with susceptibly to Crohn's disease in a region of chromosome 16 previously found to be linked to susceptibility to Crohn's disease.
  • microsatellite markers were genotyped and tested for association to Crohn's disease using the transmission disequilibrium test. A borderline significant association was found between one allele of the microsatellite marker Dl 6Sl 36. Eleven additional SNPs were selected from surrounding regions and several SNPs showed significant association.
  • the three main variants (R702W, G908R, and 1007fs) represented 32%, 18%, and 31%, respectively, of the total CD mutations, whereas the total of the 27 rare mutations represented 19% of DCMs. Altogether, 93% of the mutations were located in the distal third of the gene. No mutations were found to be associated with UC. In contrast, 50% of patients with CD carried at least one DCM, including 17% who had a double mutation. DRUG SCREENING
  • the present invention also provides novel targets and methods for the screening of drug candidates or leads.
  • the methods include binding assays and/or functional assays, and may be performed in vitro, in cell systems, in animals, etc.
  • a particular object of this invention resides in a method of selecting biologically active compounds, said method comprising contacting in vitro a test compound with an OTOA gene or polypeptide according to the present invention and determining the ability of said test compound to bind said OTOA gene or polypeptide. Binding to said gene or polypeptide provides an indication as to the ability of the compound to modulate the activity of said target, and thus to affect a pathway leading to autism, an autism spectrum disorder, or an autism-associated disorder in a subject.
  • the method comprises contacting in vitro a test compound with an OTOA polypeptide or a fragment thereof according to the present invention and determining the ability of said test compound to bind said OTOA polypeptide or fragment.
  • the fragment preferably comprises a binding site of the OTOA polypeptide.
  • said OTOA gene or polypeptide or a fragment thereof is an altered or mutated OTOA gene or polypeptide or a fragment thereof comprising the alteration or mutation.
  • a particular object of this invention resides in a method of selecting compounds active on autism, autism spectrum disorders, and autism-associated disorders, said method comprising contacting in vitro a test compound with an OTOA polypeptide according to the present invention or binding site-containing fragment thereof and determining the ability of said test compound to bind said OTOA polypeptide or fragment thereof.
  • said OTOA polypeptide or a fragment thereof is an altered or mutated OTOA polypeptide or a fragment thereof comprising the alteration or mutation.
  • the method comprises contacting a recombinant host cell expressing an OTOA polypeptide according to the present invention with a test compound, and determining the ability of said test compound to bind said OTOA and to modulate the activity of OTOA polypeptide.
  • said OTOA polypeptide or a fragment thereof is an altered or mutated OTOA polypeptide or a fragment thereof comprising the alteration or mutation.
  • the determination of binding may be performed by various techniques, such as by labeling of the test compound, by competition with a labeled reference ligand, etc.
  • a further object of this invention resides in a method of selecting biologically active compounds, said method comprising contacting in vitro a test compound with an OTOA polypeptide according to the present invention and determining the ability of said test compound to modulate the activity of said OTOA polypeptide.
  • said OTOA polypeptide or a fragment thereof is an altered or mutated OTOA polypeptide or a fragment thereof comprising the alteration or mutation.
  • a further object of this invention resides in a method of selecting biologically active compounds, said method comprising contacting in vitro a test compound with an OTOA gene according to the present invention and determining the ability of said test compound to modulate the expression of said OTOA gene.
  • said OTOA gene or a fragment thereof is an altered or mutated OTOA gene or a fragment thereof comprising the alteration or mutation.
  • this invention relates to a method of screening, selecting or identifying active compounds, particularly compounds active on autism, an autism spectrum disorder, or an autism-associated disorder, the method comprising contacting a test compound with a recombinant host cell comprising a reporter construct, said reporter construct comprising a reporter gene under the control of an OTOA gene promoter, and selecting the test compounds that modulate (e.g. stimulate or reduce) expression of the reporter gene.
  • said OTOA gene promoter or a fragment thereof is an altered or mutated OTOA gene promoter or a fragment thereof comprising the alteration or mutation.
  • the modulation is an inhibition.
  • the modulation is an activation.
  • test compounds may be assayed in parallel.
  • the test compound may be of various origin, nature and composition. It may be any organic or inorganic substance, such as a lipid, peptide, polypeptide, nucleic acid, small molecule, etc., in isolated or in mixture with other substances.
  • the compounds may be all or part of a combinatorial library of products, for instance.
  • a further object of this invention is a pharmaceutical composition
  • a pharmaceutical composition comprising (i) an OTOA polypeptide or a fragment thereof, a nucleic acid encoding an OTOA polypeptide or a fragment thereof, a vector or a recombinant host cell as described above and (ii) a pharmaceutically acceptable carrier or vehicle.
  • the invention also relates to a method of treating or preventing autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising administering to said subject a functional (e.g., wild-type) OTOA polypeptide or a nucleic acid encoding the same.
  • a functional e.g., wild-type
  • An other embodiment of this invention resides in a method of treating or preventing autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising administering to said subject a compound that modulates, preferably that activates or mimics, expression or activity of an OTOA gene or protein according to the present invention.
  • Said compound can be an agonist or an antagonist of OTOA, an antisense or a RNAi of OTOA, an antibody or a fragment or a derivative thereof specific to an OTOA polypeptide according to the present invention.
  • the modulation is an inhibition.
  • the modulation is an activation.
  • the invention also relates, generally, to the use of a functional OTOA polypeptide, a nucleic acid encoding the same, or a compound that modulates expression or activity of an
  • OTOA gene or protein according to the present invention in the manufacture of a pharmaceutical composition for treating or preventing autism, an autism spectrum disorder, or an autism-associated disorder in a subject.
  • Said compound can be an agonist or an antagonist of OTOA, an antisense or a RNAi of OTOA, an antibody or a fragment or a derivative thereof specific to an OTOA polypeptide according to the present invention.
  • the modulation is an inhibition.
  • the modulation is an activation.
  • the present invention demonstrates the correlation between autism, autism spectrum disorders, and autism-associated disorders and the OTOA gene locus.
  • the invention thus provides a novel target of therapeutic intervention.
  • Various approaches can be contemplated to restore or modulate the OTOA activity or function in a subject, particularly those carrying an altered OTOA gene locus.
  • Supplying wild-type function to such subjects is expected to suppress phenotypic expression of autism, autism spectrum disorders, and autism-associated disorders in a pathological cell or organism.
  • the supply of such function can be accomplished through gene or protein therapy, or by administering compounds that modulate or mimic OTOA polypeptide activity (e.g., agonists as identified in the above screening assays).
  • the wild-type OTOA gene or a functional part thereof may be introduced into the cells of the subject in need thereof using a vector as described above.
  • the vector may be a viral vector or a plasmid.
  • the gene may also be introduced as naked DNA.
  • the gene may be provided so as to integrate into the genome of the recipient host' cells, or to remain extra- chromosomal. Integration may occur randomly or at precisely defined sites, such as through homologous recombination.
  • a functional copy of the OTOA gene may be inserted in replacement of an altered version in a cell, through homologous recombination. Further techniques include gene gun, liposome-mediated transfection, cationic lipid-mediated transfection, etc.
  • Gene therapy may be accomplished by direct gene injection, or by administering ex vivo prepared genetically modified cells expressing a functional OTOA polypeptide.
  • OTOA activity e.g., peptides, drugs, OTOA agonists, or organic compounds
  • peptides, drugs, OTOA agonists, or organic compounds may also be used to restore functional OTOA activity in a subject or to suppress the deleterious phenotype in a cell.
  • Restoration of functional OTOA gene function in a cell may be used to prevent the development of autism, an autism spectrum disorder, or an autism-associated disorder or to reduce progression of said diseases.
  • Such a treatment may suppress the autism-associated phenotype of a cell, particularly those cells carrying a deleterious allele.
  • a further aspect of this invention resides in novel products for use in diagnosis, therapy or screening. These products comprise nucleic acid molecules encoding an OTOA polypeptide or a fragment thereof, vectors comprising the same, recombinant host cells and expressed polypeptides.
  • the invention concerns an altered or mutated OTOA gene or a fragment thereof comprising said alteration or mutation.
  • the invention also concerns nucleic acid molecules encoding an altered or mutated OTOA polypeptide or a fragment thereof comprising said alteration or mutation. Said alteration or mutation modifies the OTOA activity. The modified activity can be increased or decreased.
  • the invention further concerns a vector comprising an altered or mutated OTOA gene or a fragment thereof comprising said alteration or mutation or a nucleic acid molecule encoding an altered or mutated OTOA polypeptide or a fragment thereof comprising said alteration or mutation, recombinant host cells and expressed polypeptides.
  • a further object of this invention is a vector comprising a nucleic acid encoding an OTOA polypeptide according to the present invention.
  • the vector may be a cloning vector or, more preferably, an expression vector, i.e., a vector comprising regulatory sequences causing expression of an OTOA polypeptide from said vector in a competent host cell.
  • vectors can be used to express an OTOA polypeptide in vitro, ex vivo or in vivo, to create transgenic or "Knock Out” non-human animals, to amplify the nucleic acids, to express antisense RNAs, etc.
  • the vectors of this invention typically comprise an OTOA coding sequence according to the present invention operably linked to regulatory sequences, e.g., a promoter, a polyA, etc.
  • regulatory sequences e.g., a promoter, a polyA, etc.
  • operably linked indicates that the coding and regulatory sequences are functionally associated so that the regulatory sequences cause expression (e.g., transcription) of the coding sequences.
  • the vectors may further comprise one or several origins of replication and/or selectable markers.
  • the promoter region may be homologous or heterologous with respect to the coding sequence, and may provide for ubiquitous, constitutive, regulated and/or tissue specific expression, in any appropriate host cell, including for in vivo use.
  • promoters examples include bacterial promoters (T7, pTAC, Trp promoter, etc.), viral promoters (LTR, TK, CMV-IE 5 etc.), mammalian gene promoters (albumin, PGK, etc), and the like.
  • the vector may be a plasmid, a virus, a cosmid, a phage, a BAC, a YAC, etc.
  • Plasmid vectors may be prepared from commercially available vectors such as pBluescript, pUC, pBR, etc.
  • Viral vectors may be produced from baculoviruses, retroviruses, adenoviruses, AAVs, etc., according to recombinant DNA techniques known in the art.
  • a particular object of this invention resides in a recombinant virus encoding an OTOA polypeptide as defined above.
  • the recombinant virus is preferably replication- defective, even more preferably selected from El- and/or E4-defective adenoviruses, Gag-, pol- and/or env-defective retroviruses and Rep- and/or Cap-defective AAVs.
  • Such recombinant viruses may be produced by techniques known in the art, such as by transfecthig packaging cells or by transient transfection with helper plasmids or viruses.
  • Typical examples of virus packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc.
  • a further object of the present invention resides in a recombinant host cell comprising a recombinant OTOA gene or a vector as defined above.
  • Suitable host cells include, without limitation, prokaryotic cells (such as bacteria) and eukaryotic cells (such as yeast cells, mammalian cells, insect cells, plant cells, etc.). Specific examples include E. coli, Kluyveromyces or Saccharomyces yeasts, mammalian cell lines (e.g., Vero cells, CHO cells, 3T3 cells, COS cells, etc.) as well as primary or established mammalian cell cultures (e.g., produced from fibroblasts, embryonic cells, epithelial cells, nervous cells, adipocytes, etc.).
  • the present invention also relates to a method for producing a recombinant host cell expressing an OTOA polypeptide according to the present invention, said method comprising (i) introducing in vitro or ex vivo into a competent host cell a recombinant nucleic acid or a vector as described above, (ii) culturing in vitro or ex vivo the recombinant host cells obtained and (iii), optionally, selecting the cells which express the OTOA polypeptide.
  • Such recombinant host cells can be used for the production of OTOA polypeptides, as well as for screening of active molecules, as described below. Such cells may also be used as a model system to study autism. These cells can be maintained in suitable culture media, such as DMEM, RPMI, HAM, etc., in any appropriate culture device (plate, flask, dish, tube, pouch, etc.).
  • GenomeHIP platform to identify the chromosome 16 susceptibility gene
  • the GenomeHIP platform was applied to allow rapid identification of an autism susceptibility gene. Briefly, the technology consists of forming pairs from the DNA of related individuals. Each DNA is marked with a specific label allowing its identification. Hybrids are then formed between the two DNAs. A particular process (WO00/53802) is then applied that selects all fragments identical-by-descent (IBD) from the two DNAs in a multi step procedure. The remaining IBD enriched DNA is then scored against a BAC clone derived DNA microarray that allows the positioning of the IBD fraction on a chromosome.
  • IBD identical-by-descent
  • BACA7ZF09, BACA7ZH09, BACA7ZD06, BACA27ZA05, BACA27ZD05 and BACA27ZC05 spanning approximately 5 megabases in the region on chromosome 16 (basesl 9333164 to 24295063), which showed significant evidence for linkage to autism (p
  • Table 2 Linkage results for chromosome 16 in the OTOA locus: Indicated is the region corresponding to 7 BAC clones with evidence for linkage. The start and stop positions of the clones correspond to their genomic locations based on NCBI Build34 with respect to the start of the chromosome (p-ter).
  • noncollageneous glycoproteins of the acellular gels of the inner ear that have been described in mammals, namely alpha-tectorin, beta-tectorin, and otogelin, are molecules unique to the inner ear.
  • Zwaenepoel et al. (2002) reported the first example of a protein, otoancorin (OTOA), specifically located at the interface between the apical surface of the sensory epithelia and their overlying acellular gels, and also entirely specific for the inner ear.
  • OTOA otoancorin
  • Mouse OTOA has a signal peptide, 1 1 potential N-glycosylation sites, and a C-terminal sequence characteristic of glycosyl phosphatidyl inositol (GPI)-linked membrane-bound proteins.
  • RT- PCR analysis detected expression of mouse OTOA only in the inner ear.
  • the protein contains a coiled coil stretch and an endoplasmic reticulum membrane domain.
  • OTOA is defective in autosomal recessive deafness DFNB22.
  • testis a lymphoma and a colon tumor.
  • otoancorin is not localised on hair bundles, it was hypothesised that a different system, possibly integrins, is responsible for their interaction with acellular matrices.
  • GPI anchor can be considered primarily as an alternative to a hydrophobic transmembrane polypeptide anchor, several other functions have been proposed for GPI anchors. These include roles in intracellular sorting, in the endocytic process of potocytosis
  • a GPI anchor may also allow a protein to associate in cholesterol and glycosphingolipid-rich lipid rafts, to be more laterally mobile in the bilayer and to be selectively released from the cell-surface by the action of phospholipases.
  • TDT transmission disequilibrium test
  • PDT pedigree disequilibrium test
  • haplotypes were constructed for SNP62, SNP67, S1MP71, SNP72 and SNP75 to identify the phase for all SMPs.
  • Haplotypes that carry allele C instead of allele T at SNP67 show evidence to be under-represented in autistic subjects.
  • An example is the haplotype A-C-A for SNP62-SNP67-SNP72.
  • Baird G Charman T, Baron-Cohen S et al. (2000) A screening instrument for autism at 18 months of age: a 6-year follow-up study. J Am Acad Child Adolesc Psychiatry, 39(6):694-
  • Otoancorin an inner ear protein restricted to the interface between the apical surface of sensory epithelia and their overlying acellular gels, is defective in autosomal recessive deafness DFNB22. Proc. Nat. Acad. Sci. 99: 6240- 6245.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'identification d'un gène humain de prédisposition à l'autisme pouvant être utilisé pour le diagnostic, la prévention et le traitement de l'autisme et de troubles associés, ainsi que pour le criblage de médicaments actifs sur le plan thérapeutique. Plus précisément, l'invention concerne le gène OTOA sur le chromosome 16 et certains allèles de celui-ci relatifs à la prédisposition à l'autisme et représentant de nouvelles cibles pour l'intervention thérapeutique. L'invention concerne des mutations spécifiques dans le gène OTOA et des produits d'expression, ainsi que des outils et des kits de diagnostic fondés sur ces mutations. Les produits de l'invention peuvent être utilisés dans le diagnostic de la prédisposition au syndrome d'Asperger, du trouble du développement profond, du retard mental, de l'anxiété, de la dépression, de troubles de l'hyperactivité avec déficit de l'attention, du retard de parole, de l'épilepsie, de trouble du métabolisme, de trouble immunitaire, de la maladie bipolaire et d'autres maladies psychiatriques et neurologiques et dans la détection, la prévention et/ou le traitement de ces maladies.
PCT/IB2005/002630 2004-07-01 2005-06-30 Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci WO2006003526A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58412704P 2004-07-01 2004-07-01
US60/584,127 2004-07-01

Publications (3)

Publication Number Publication Date
WO2006003526A2 true WO2006003526A2 (fr) 2006-01-12
WO2006003526A8 WO2006003526A8 (fr) 2006-03-02
WO2006003526A3 WO2006003526A3 (fr) 2006-06-15

Family

ID=35429403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002630 WO2006003526A2 (fr) 2004-07-01 2005-06-30 Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci

Country Status (1)

Country Link
WO (1) WO2006003526A2 (fr)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BARNBY GABRIELLE ET AL: "Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: Evidence of association at GRIN2A and ABAT" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 76, no. 6, June 2005 (2005-06), pages 950-966, XP002358259 ISSN: 0002-9297 *
CRAWFORD L ET AL: "Fine-scale SNP genotyping for Autism using Single Base Extension and tag arrays" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 69, no. 4 Supplement, October 2001 (2001-10), page 508, XP002358258 & 51ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICS; SAN DIEGO, CALIFORNIA, USA; OCTOBER 12-16, 2001 ISSN: 0002-9297 *
CRAWFORD L R ET AL: "THE CHARACTERIZATION AND GENOTYPING OF SINGLE NUCLEOTIDE POLYMORPHISMS IN CODING REGIONS OF BRAIN-EXPRESSED AUTISM CANDIDATE GENES" AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, no. 4, SUPPL 2, October 2000 (2000-10), page 351, XP001098557 ISSN: 0002-9297 *
DANIELS RACHAEL J ET AL: "Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16" HUMAN MOLECULAR GENETICS, vol. 10, no. 4, 15 February 2001 (2001-02-15), pages 339-352, XP002358255 ISSN: 0964-6906 *
INTERNATIONAL MOLECULAR GENETIC STUDY OF AUTISM CONSORTIUM (IMGSAC): "A genomewide screen for autism: Strong evidence for linkage to chromosomes 2q, 7q, and 16p" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 69, no. 3, September 2001 (2001-09), pages 570-581, XP002358256 ISSN: 0002-9297 *
LAURITSEN M B ET AL: "The genetics of autism" ACTA PSYCHIATRICA SCANDINAVICA, vol. 103, no. 6, June 2001 (2001-06), pages 411-427, XP002358261 ISSN: 0001-690X *
SMALLEY SUSAN L ET AL: "Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 71, no. 4, October 2002 (2002-10), pages 959-963, XP002358257 ISSN: 0002-9297 *
ZWAENEPOEL INGRID ET AL: "Otoancorin, an inner ear protein restricted to the interface between the apical surface of sensory epithelia and their overlying acellular gels, is defective in autosomal recessive deafness DFNB22" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 9, 30 April 2002 (2002-04-30), pages 6240-6245, XP002358260 ISSN: 0027-8424 cited in the application *

Also Published As

Publication number Publication date
WO2006003526A3 (fr) 2006-06-15
WO2006003526A8 (fr) 2006-03-02

Similar Documents

Publication Publication Date Title
AU2005258838B2 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
AU2006215385B2 (en) Uses of human autism susceptibility gene encoding a kinase
US20100240539A1 (en) Human Autism Susceptibility Gene Encoding PRKCB1 and Uses Thereof
EP1656458B1 (fr) Gene humain de susceptibilite a l'autisme et ses utilisations
AU2006225995B2 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
US20080213765A1 (en) Human Autism Susceptibility Genes Encoding a Neurotransmitter Transporter and Uses Thereof
US20090208482A1 (en) Human obesity susceptibility gene encoding a member of the neurexin family and uses thereof
WO2006003526A2 (fr) Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci
AU2005254806B2 (en) Human obesity susceptibility gene encoding a potassium voltage-gated channel and uses thereof
US20080286765A1 (en) Human Obesity Susceptibility Gene Encoding a Taste Receptor and Uses Thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 02/2006 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A) DATED 05-04-2007

122 Ep: pct application non-entry in european phase

Ref document number: 05774233

Country of ref document: EP

Kind code of ref document: A2